| Mechanism of CYP2C9 inhibition by flavones and flavonols D Si, Y Wang, YH Zhou, Y Guo, J Wang, H Zhou, ZS Li, JP Fawcett Drug metabolism and disposition 37 (3), 629-634, 2009 | 199 | 2009 |
| Identification of a novel variant CYP2C9 allele in Chinese D Si, Y Guo, Y Zhang, L Yang, H Zhou, D Zhong Pharmacogenetics and Genomics 14 (7), 465-469, 2004 | 128 | 2004 |
| Role of CYP2C9 and its variants (CYP2C9* 3 and CYP2C9* 13) in the metabolism of lornoxicam in humans Y Guo, Y Zhang, Y Wang, X Chen, D Si, D Zhong, JP Fawcett, H Zhou Drug metabolism and disposition 33 (6), 749-753, 2005 | 107 | 2005 |
| Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype Y Zhang, D Zhong, D Si, Y Guo, X Chen, H Zhou British journal of clinical pharmacology 59 (1), 14-17, 2005 | 83 | 2005 |
| Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects Y Zhang, D Si, X Chen, N Lin, Y Guo, H Zhou, D Zhong British journal of clinical pharmacology 64 (1), 67-74, 2007 | 81 | 2007 |
| Catalytic activities of human cytochrome P450 2C9* 1, 2C9* 3 and 2C9* 13 Y Guo, Y Wang, D Si, PJ Fawcett, D Zhong, H Zhou Xenobiotica 35 (9), 853-861, 2005 | 61 | 2005 |
| On the human CYP2C9* 13 variant activity reduction: a molecular dynamics simulation and docking study YH Zhou, QC Zheng, ZS Li, Y Zhang, M Sun, CC Sun, D Si, L Cai, Y Guo, ... Biochimie 88 (10), 1457-1465, 2006 | 45 | 2006 |
| Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol D Si, J Wang, Y Xu, X Chen, M Zhang, H Zhou Journal of cardiovascular pharmacology 64 (4), 306-309, 2014 | 33 | 2014 |
| Two Novel SCN9A Gene Heterozygous Mutations May Cause Partial Deletion of Pain Perception R Yuan, X Zhang, Q Deng, D Si, Y Wu, F Gao, B Zhou Pain medicine 12 (10), 1510-1514, 2011 | 31 | 2011 |
| Genetic characteristics and migration history of a bronze culture population in the West Liao-River valley revealed by ancient DNA H Li, X Zhao, Y Zhao, C Li, D Si, H Zhou, Y Cui Journal of human genetics 56 (12), 815-822, 2011 | 30 | 2011 |
| Whole exome sequencing identifies a novel EMDmutation in a Chinese family with dilated cardiomyopathy M Zhang, J Chen, D Si, Y Zheng, H Jiao, Z Feng, Z Hu, R Duan BMC medical genetics 15, 1-7, 2014 | 28 | 2014 |
| Impact of cytochrome P450 CYP2C9 variant allele CYP2C9* 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects YF Zhang, XY Chen, YJ Guo, DY Si, H Zhou, DF Zhong Yao xue xue bao= Acta pharmaceutica Sinica 40 (9), 796-799, 2005 | 17 | 2005 |
| Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2 Dayong Si, Juan Wang, Yifan Zhang, Dafang Zhong Biopharmaceutics & Drug Disposition, epub online 8 AUG 2012, 2012 | 8* | 2012 |
| Comments on" NEMO Gene Mutations in Chinese Patients With Incontinentia Pigmenti" D Si, J Liu Journal of the Formosan Medical Association= Taiwan yi zhi 117 (10), 946, 2018 | 3 | 2018 |
| Influence of CYP2C9 and CYP2C19 Hui Z, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects Z Yifan, S Dayong, C Xiaoyan, L Nan, G Yingjie, Z Hui Br J Clin Pharmacol 64 (1), 67-74, 2007 | 2 | 2007 |
| Questionnaire survey on association between preeclampsia and incontinentia pigmenti X Sun, Y Huang, D Si, S Gao, P Wang Journal of Obstetrics and Gynaecology Research 45 (7), 1363-1370, 2019 | 1 | 2019 |
| Effects of the Active Components of Chinese Herbs on CYP Related Genes Express ion in HepG2 Cells Y Guo, J Zhang, D SI, J GU, H Zhou Traditional Chinese Drug Research & Clinical Pharmacology, 1993 | 1 | 1993 |
| Ancient DNA Analysis of Human Remains before Qin Dynasty in the Great Wall Belt in Inner Mongolia Ancient DNA Analysis of Human Remains before Qin Dynasty in the Great Wall … H Li, X Zhao, Y Zhao, C LI, D SI, H ZHOU, Y CUI Journal of human genetics 56 (12), 815-822, 2011 | | 2011 |
| Role of Residue 90 in Catalysis of Cytochrome P450 2C9 Y WANG, Y ZHOU, Y GUO, X XU, D SI, H ZHOU, Z LI | | 2009 |
| PHARMACOKINETICS OF CARISOPRODOL AT TWO DOSAGE LEVELS AND INFLUENCE OF CYP2C19 POLYMORPHISM ON ITS PHARMACOKINETICS IN HEALTHY CHINESE VOLUNTEERS Y Zhang, D Zhong, X Chen, D Si, H Zhou DRUG METABOLISM REVIEWS 40, 153-153, 2008 | | 2008 |
